Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00076349
Status:
COMPLETED
Last Update Posted:
2014-05-09
First Post:
2004-01-20
Brief Title:
SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkins Lymphoma NHL
Sponsor:
Cephalon
Organization:
Teva Branded Pharmaceutical Products RD Inc